Table 1.
Patient characteristics of 25 patients with hypertrophic cardiomyopathy.
| Age, mean (years) | 56.8 | ±12.9 |
| Male | 19 | 76% |
| Body-mass index (kg/m2) | 28.6 | ±4.4 |
| Body surface area (m2) | 2.05 | ±0.27 |
| Primary prevention | 22 | 88% |
| Diabetes mellitus | 5 | 20% |
| Hypertension | 5 | 20% |
| Genopositive | 13 | 52% |
| Alcohol septal ablation | 0 | 0% |
| Myectomy | 8 | 32% |
| Atrial fibrillation | 7 | 28% |
| Medication | ||
| Beta-blocker | 22 | 88% |
| Calcium channel blocker | 4 | 16% |
| Sotalol | 0 | 0% |
| Disopyramide | 0 | 0% |
| Amiodarone | 1 | 4% |
| ACE-I/ARB | 9 | 36% |
| Aldosterone receptor blocker | 3 | 12% |
| Acetylsalicylic acid | 4 | 16% |
| Warfarin | 2 | 8% |
| Novel oral anticoagulant | 5 | 20% |
| Hemodynamics at PET | ||
| Systolic blood pressure (mmHg) | 128 | ±17 |
| Diastolic blood pressure (mmHg) | 75 | ±15 |
| Heart rate (beats per minute) | 63 | ±9 |
| Ventricular pacing at PET | ||
| Intrinsic rhythm | 20 | 80% |
| Pacing | 4 | 16% |
| Mixed (intrinsic and pacing) | 1 | 4% |
| Echocardiography | ||
| Left atrial diameter (mm) | 48 | ±10 |
| Left atrial size/body surface area (ml/m2) | 53 | ±41 |
| Left ventricular diameter, diastole (mm) | 49 | ±6 |
| Left ventricular diameter, systole (mm) | 34 | ±6 |
| Left ventricular outflow tract gradient (mmHg) | 8 | ±5 |
| Left ventricular outflow obstruction*(≥30 mmHg) | 2 | 13% |
| Left ventricular ejection fraction (%) | 57 | ±9 |
| Maximal wall thickness (mm) | 20 | ±4 |
| Tricuspid annular plane systolic excursion (mm) | 22 | ±4 |
| Systolic pulmonary artery pressure (mmHg) | 32 | ±10 |
ACE-I/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; PET, positron emission tomography.
* ≥30 mmHg at rest or Valsalva maneuver.